Institutional review board

SeriousFun Children's Network Names Pediatric and Camp Medicine Expert Dr. Laura Blaisdell as New Medical Advisor

Retrieved on: 
Tuesday, August 22, 2023
Heart, Maine Medical Center, Institutional review board, Medicine, University, SeriousFun Children's Network, Policy, Mercy Hospital, Human, Research, AAP, History, Carleton College, Blaisdell, IRB, Chief Medical Advisor to the President, Knowledge, Otto Lilienthal, Growth, Caregiver, Safety, Nursing, Pediatrics

NORWALK, Conn., Aug. 22, 2023 /PRNewswire/ -- SeriousFun Children's Network (SeriousFun), the leading network of medical specialty camps in the world, providing camp experiences to children living with more than 130 medical conditions, has named Dr. Laura Blaisdell as the organization's Medical Advisor. Blaisdell will play an integral part of the SeriousFun team where she will provide medical support and resources to help strengthen medical systems and safety, evaluate and guide growth and expansion, and serve as the organization's voice and representative within the medical community.

Key Points: 
  • NORWALK, Conn., Aug. 22, 2023 /PRNewswire/ -- SeriousFun Children's Network (SeriousFun), the leading network of medical specialty camps in the world, providing camp experiences to children living with more than 130 medical conditions, has named Dr. Laura Blaisdell as the organization's Medical Advisor.
  • As a public health-trained pediatrician, she brings extensive knowledge and skill in pediatric medicine to our growing organization, as well as being an expert in vaccine policy and camp medicine," said Blake Maher, CEO of SeriousFun.
  • Dr. Blaisdell's camp medicine experience comes from time spent as Medical Director at Camp Winnebago in Maine.
  • "SeriousFun has a strong history of delivering camp experiences that have a lasting impact on so many individuals and communities.

BIOXCEL THERAPEUTICS, INC. (NASDAQ: BTAI) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioXcel Therapeutics, Inc.

Retrieved on: 
Tuesday, August 22, 2023
LLP, Institutional review board, Record, Food and Drug Administration Amendments Act of 2007, Dementia, District court, Patient, Advertising, Complaint, Defendant, Court, Action Replay, FDA, Therapy, News, Agitation, Food, Safety, Cryptocurrency, Pharmaceutical industry, Security (finance)

If you purchased or acquired BioXcel securities, and/or would like to discuss your legal rights and options please visit BioXcel Therapeutics, Inc.

Key Points: 
  • If you purchased or acquired BioXcel securities, and/or would like to discuss your legal rights and options please visit BioXcel Therapeutics, Inc.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you purchased or acquired BioXcel securities, and/or would like to discuss your legal rights and options please visit BioXcel Therapeutics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ImmunityBio, BioXcel, and Seagate and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, August 22, 2023
GMP, Institutional review board, Good manufacturing practice, CMOS, Seagate, Patient, BLA, News, Commerce, Software, U.S. Department of Commerce Office of Security, P.C, Policy, Infection, EAR, Name, Food and Drug Administration, Dementia, FDA, Entity List, Safety, Vaccine, Biologics license application, BIS, Shareholder, Office of Inspector General, U.S. Department of Health and Human Services, Record, Immunotherapy, HDD, Immune system, Defendant, United, Therapy, Agitation, Jordan Economic and Commerce Bureau, Acceleration, Seagate Technology, Person, Nursing, Nature, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Cryptocurrency, Audit, Huawei, ImmunityBio COVID-19 vaccine

The Company offers immunotherapy and cell therapy platforms, including, inter alia, antibody cytokine fusion protein N-803, commercially referred to as “Anktiva”.

Key Points: 
  • The Company offers immunotherapy and cell therapy platforms, including, inter alia, antibody cytokine fusion protein N-803, commercially referred to as “Anktiva”.
  • The Company uses third-party contract manufacturing organizations (“CMOs”) to produce certain of its product candidates, including Anktiva.
  • In May 2022, ImmunityBio submitted a Biologics License Application (“BLA”) for Anktiva to the U.S. Food and Drug Administration (“FDA”).
  • For more information on the Seagate class action go to: https://bespc.com/cases/STX

BioXcel Therapeutics, Inc: Please contact the Portnoy Law Firm to recover your losses; September 5, 2023 deadline.

Retrieved on: 
Monday, August 21, 2023
Institutional review board, Maintenance, Record, Dementia, Patient, Defendant, FDA, Therapy, Agitation, Pharmaceutical industry

LOS ANGELES, Aug. 21, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) investors that a lawsuit filed on behalf of investors that purchased BioXcel securities between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”).

Key Points: 
  • LOS ANGELES, Aug. 21, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI) investors that a lawsuit filed on behalf of investors that purchased BioXcel securities between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”).
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

BTAI CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages BioXcel Therapeutics (BTAI) Investors with Substantial Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending

Retrieved on: 
Monday, August 21, 2023
Institutional review board, Alzheimer's disease, Person, Record, Patient, Hagens Berman, SAN, Defendant, FDA, Therapy, News, Safety, Protocol, Pharmaceutical industry, Medical device

SAN FRANCISCO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now .
  • BioXcel Therapeutics, Inc. (BTAI) Securities Fraud Class Action:
    The litigation focuses on BioXcel’s statements and omissions regarding its TRANQUILITY II study evaluating its Alzheimer candidate drug BXCL501.
  • “We’re focused on investors’ losses and proving BioXcel misled investors about its adherence to the trial protocol and the true commercial prospects for BXCL501,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in BioXcel and have substantial losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .

BTAI CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages BioXcel Therapeutics (BTAI) Investors with Substantial Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending

Retrieved on: 
Monday, August 21, 2023
Institutional review board, Alzheimer's disease, Person, Record, Patient, Hagens Berman, SAN, Defendant, FDA, Therapy, News, Safety, Protocol, Pharmaceutical industry, Medical device

SAN FRANCISCO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now .
  • BioXcel Therapeutics, Inc. (BTAI) Securities Fraud Class Action:
    The litigation focuses on BioXcel’s statements and omissions regarding its TRANQUILITY II study evaluating its Alzheimer candidate drug BXCL501.
  • “We’re focused on investors’ losses and proving BioXcel misled investors about its adherence to the trial protocol and the true commercial prospects for BXCL501,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in BioXcel and have substantial losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of BioXcel Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 5, 2023 – (NASDAQ: BTAI)

Retrieved on: 
Monday, August 21, 2023
Institutional review board, Record, Dementia, Patient, NEXT, Fraud, FDA, Therapy, Agitation, Safety, Holding company, Security (finance)

Appointment as lead plaintiff is not required to partake in any recovery.

Key Points: 
  • Appointment as lead plaintiff is not required to partake in any recovery.
  • DEADLINE: September 5, 2023 Shareholders should not delay in registering for this class action.
  • The deadline to seek to be a lead plaintiff is September 5, 2023.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

Calling All BioXcel Therapeutics, Inc. (BTAI) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses!

Retrieved on: 
Monday, August 21, 2023
Institutional review board, Record, Person, Dementia, Patient, Complaint, Defendant, Court, FDA, Therapy, Agitation, Safety, Pharmaceutical industry

Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/btai .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/btai .
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • If you suffered a loss in BioXcel you have until September 5, 2023, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BTAI

Retrieved on: 
Sunday, August 20, 2023
Titan, Institutional review board, Dexmedetomidine, Class, Record, Agitation, Dementia, Patient, Advertising, Court, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, I-Space (Chinese company), Food, Safety, Insurance, Tobacco

WHAT TO DO NEXT: To join the BioXcel Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=17579 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioXcel Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=17579 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit

Retrieved on: 
Saturday, August 19, 2023
Insurance, LLP, COPY, Lead, Record, Institutional review board, Nursing, Dementia, District court, Patient, Court, FDA, Therapy, News, Agitation, Safety, Pharmaceutical industry

The action charges BioXcel with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges BioXcel with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of BioXcel’s materially misleading statements and omissions to the public, BioXcel’s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages BioXcel investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The class action complaint against BioXcel, captioned Katelyn Martin v. BioXcel Therapeutics, et al.